Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer

The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...12/12/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news